AddLife AB (publ) (ALIF_B) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Addlife Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.837 Good morning, everyone, and warm welcome to the AdLife third quarter report. 00:00:04.837 -- 00:00:08.762 As usual, we will take you through the numbers and description of what has happened in 00:00:08.762 -- 00:00:13.708 the company during the quarter. Then we will open up for a Q&A session. 00:00:13.708 -- 00:00:18.414 And after that, as usual, we encourage you to stay on for a few more minutes to see an 00:00:18.414 -- 00:00:21.138 interesting video from one of our companies. 00:00:21.138 -- 00:00:26.064 This time around is from Health Care 21 Ireland, a very important piece of the puzzle 00:00:26.064 -- 00:00:30.789 as we are growing throughout Europe and an important platform acquisition. 00:00:30.789 -- 00:00:34.193 So let's get going with the highlights of the third quarter. 00:00:34.193 -- 00:00:38.619 So the AdLife companies all had a good quarter in the third quarter of 2025. 00:00:38.619 -- 00:00:43.765 We saw a strong EBITDA improvement in both business areas. 00:00:43.765 -- 00:00:49.673 We saw a healthy customer demand, currency adjusted growth increased by 7%, 6% 00:00:49.673 -- 00:00:53.525 organic and a nice addition of 1% from acquisitions. 00:00:53.525 -- 00:00:58.590 The growth in Labtech was really strong, 9% excluding currency effects, and on the 00:00:58.590 -- 00:01:02.913 Medtech side, a very healthy demand in spite of the fact that we are updating our product 00:01:02.913 -- 00:01:07.237 portfolio and we saw a little bit of a weakness in capital sales. 00:01:07.237 -- 00:01:11.301 So 5% growth in Medtech, a strong quarter. 00:01:11.301 -- 00:01:15.565 We are driving profitability improvement initiatives in a handful of companies. 00:01:15.565 -- 00:01:19.929 These are progressing quite well, but there is m...